Edwyn

Edwyn Search SEC Edgar companies...⌘K

Investing IdeasCompare Stocks

NVDA TSLA AAPL

Overview

ValuationValuation Calculator Relative Valuation Intrinsic Value (DCF)

FinancialsIncome Statement Balance Sheet Cash Flow

Explore Demo

Relative Valuation

BHC Relative Valuation

Compare public peers against market pricing to see what the current peer set implies for fair value.

Adjust Assumptions

Peer Assumption Controls

Adjust the usable peer mix to instantly see how different valuation multiples impact the blended fair value.

Peer-Implied Fair Value

$92.65

Blended value per share

Peers imply 1,365.9% upside

Weighting Mixer

EV / EBITDA

34%

Price / Sales

33%

Price / Earnings

33%

Value Contribution Breakdown

EV / EBITDA

Implied peer value: $66.89B

$22.74B34% Weight

Price / Sales

Implied peer value: $32.47B

$10.71B33% Weight

Price / Earnings

Implied peer value: $3.61B

$1.19B33% Weight

5 PeersView Full Peer Table

Equal-Weight Baseline

Premium 0.9% vs Base

$34.32B

This represents the simple average of all usable peer methods before your custom weighting adjustments are applied.

Base fair value / share:$91.78

Intrinsic Cross-Check

Underwrite Your Own Assumptions

Move beyond relative peer pricing. Use intrinsic valuation when you want to underwrite precise cash-flow forecasts, discount rates, and complex scenario ranges.

Open Intrinsic Model

Spreadsheet Data

Underlying Peer Data

Audit the saved peer set and the method inputs behind the blended fair value.

Peer data table

Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.

Peer	Price	Market Cap	Enterprise Value	Revenue

Adjust Assumptions

Peer Assumption Controls

Adjust the usable peer mix to instantly see how different valuation multiples impact the blended fair value.

Peer-Implied Fair Value

$92.65

Blended value per share

Peers imply 1,365.9% upside

Weighting Mixer

EV / EBITDA

34%

Price / Sales

33%

Price / Earnings

33%

Value Contribution Breakdown

EV / EBITDA

Implied peer value: $66.89B

$22.74B34% Weight

Price / Sales

Implied peer value: $32.47B

$10.71B33% Weight

Price / Earnings

Implied peer value: $3.61B

$1.19B33% Weight

5 PeersView Full Peer Table

Equal-Weight Baseline

Premium 0.9% vs Base

$34.32B

This represents the simple average of all usable peer methods before your custom weighting adjustments are applied.

Base fair value / share:$91.78

Intrinsic Cross-Check

Underwrite Your Own Assumptions

Move beyond relative peer pricing. Use intrinsic valuation when you want to underwrite precise cash-flow forecasts, discount rates, and complex scenario ranges.

Open Intrinsic Model

Spreadsheet Data

Underlying Peer Data

Audit the saved peer set and the method inputs behind the blended fair value.

Peer data table

Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.

Peer	Price	Market Cap	Enterprise Value	Revenue

Weighted Averages

See which peer averages feed the weighted fair value and which methods are excluded.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status
EV / EBITDA EVActive	Enterprise Multiple	19.40x	5/5	$66.89B	$178.85	Included in the active peer mix.
Price / Sales PSActive	Equity Multiple	3.16x	5/5	$32.47B	$86.82	Included in the active peer mix.
Price / Earnings PEActive	Equity Multiple	23.02x	5/5	$3.61B	$9.66	Included in the active peer mix.

Peer data table

Open the saved peer table used to audit the fair value view.

Peer	Price	Market Cap	Enterprise Value	Revenue	EBITDA	Net Income	P/E	P/S	EV/EBITDA
AB ABBV AbbVie Inc. FY ended Feb 10, 2026	$255.48	$451.46B	$508.66B	$61.16B	$17.62B	$4.23B	108.25x	7.38x	24.66x
OG OGN Organon & Co. FY ended Feb 17, 2026	$13.76	$3.61B	$13.79B	$6.22B	$1.29B	$187.00M	19.11x	0.58x	10.69x
TE TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD FY ended Dec 31, 2025	$36.44	$42.46B	$63.85B	$17.26B	$3.15B	$1.41B	30.12x	2.46x	15.58x
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026	$43.73	$2.54B	$2.07B	$718.95M	$60.82M	-$38.55M	-64.31x	3.54x	29.22x
AN ANIP ANI PHARMACEUTICALS INC FY ended Dec 31, 2025	$72.83	$1.64B	$2.20B	$883.37M	$187.66M	$78.34M	21.94x	1.85x	10.07x

Weighted Averages

Open the peer-average inputs behind the weighted result.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status
EV / EBITDA EVActive	Enterprise Multiple	19.40x	5/5	$66.89B	$178.85	Included in the active peer mix.
Price / Sales PSActive	Equity Multiple	3.16x	5/5	$32.47B	$86.82	Included in the active peer mix.
Price / Earnings PEActive	Equity Multiple	23.02x	5/5	$3.61B	$9.66	Included in the active peer mix.